Updates in Cardiology
Top News / Myocardial infarction: Heparin vs Bivalirudin
–
” Even if Heparin alone had produced statistically similar outcomes to Bivalirudin, it would have been a win for Heparin. A drug that costs less than a 1/400th of another that has similar efficacy and safety ought to be used preferentially “ Peter Berger and James Blankenship of Geisinger Health System, in Pennsylvania, USA
Myocardial infarction: Heparin rather than Bivalirudin after primary percutaneous coronary intervention can improve outcomes and save health budgets millions
A new study has compared outcomes for two drugs used to prevent blood clot formation during emergency myocardial infarction treatment. The study suggests that use of one of the drugs, Heparin, could …
Focus On: Diabetes mellitus & Heart failure
Sitagliptin therapy has shown no sign of increasing risk for all-cause hospitalization or death ( primary end point ), but the use of Sitagliptin was associated with greater risk of hospitalization for heart failure
Sitagliptin linked to increased risk of heart failure-related hospitalizations among patients with type 2 diabetes with pre-existing heart failure
The study objective was to evaluate the effects of Sitagliptin ( Januvia ), a dipeptidyl peptidase 4 inhibitor, in patients with type 2 diabetes ( T2D ) and heart failure ( HF ). There is uncertain …
News
Benefits of percutaneous MitraClip device for mitral regurgitation in high-surgical-risk patients: EVEREST II trial
The EVEREST II ( Endovascular Valve Edge-to-Edge REpair Study ) High-Risk registry and REALISM Continued Access Study High-Risk Arm are prospective registries of patients who received the MitraClip de …
Nonselective agents with greater inhibition of Cox-1 than Cox-2, such as Ibuprofen, were not associated with increased cardiovascular risk
Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs ( NSAIDs ) are sparse. It has been hypothesized that regular NSAID use is associated with increased risk for cardi …
High-potency statin reduces mortality in survivors of an acute myocardial infarction
A study has determined all-cause mortality in patients with a first myocardial infarct who were treated with Simvastatin ( Zocor ) compared with high-potency statin and Simvastatin / Ezetimibe